DelveInsight’s “Pouchitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Pouchitis, historical and forecasted epidemiology as well as the Pouchitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Pouchitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Pouchitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pouchitis Market Insights

Pouchitis Overview

Pouchitis is inflammation that occurs in the lining of a pouch created during surgery to treat ulcerative colitis or certain other diseases. Many people with ulcerative colitis need to have their diseased colon removed and the bowel reconnected with a procedure called ileoanal anastomosis (J-pouch) surgery.

Some of the key facts of the Pouchitis Market Report: 

• The Pouchitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per Otero-Regino et. al. (2021), the incidence of pouchitis varies over time. At 1, 5 and 10 years, its incidence is 20%, 40% and 50%, respectively. At 30 years after surgery, it may affect 80% of patients
• According to the analysis of Barnes et. al. (2020) in patients who underwent proctocolectomy with IPAA for ulcerative colitis (UC), in a geographically diverse population, 48% of patients with UC developed Pouchitis within the first 2 years after ileal pouch-anal anastomosis (IPAA)
• Key Pouchitis Companies: Novo Nordisk, Applied Molecular Transport, Takeda Pharmaceutical Company Limited, AstraZeneca, Pfizer, Inc., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and others
• Key Pouchitis Therapies: Liraglutide, AMT-101, and others
• The Pouchitis market epidemiology based on gender analyzed that male gender is associated with a high risk for chronic antibiotic-refractory pouchitis

Get a Free sample for the Pouchitis Market Report – 

https://www.delveinsight.com/sample-request/pouchitis-market

Key benefits of the Pouchitis Market report:

1. Pouchitis market report covers a descriptive overview and comprehensive insight of the Pouchitis Epidemiology and Pouchitis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Pouchitis market report provides insights on the current and emerging therapies.
3. Pouchitis market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Pouchitis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Pouchitis market.

Download the report to understand which factors are driving Pouchitis epidemiology trends @ Pouchitis Epidemiological Insights 

Pouchitis Market  

The dynamics of the Pouchitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“In February 2022, Takeda announced that the European Commission had granted marketing authorization for the IV formulation of vedolizumab for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC), and have had an inadequate response with or lost response to antibiotic therapy.”

Pouchitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pouchitis Epidemiology Segmentation:

The Pouchitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Pouchitis
• Prevalent Cases of Pouchitis by severity
• Gender-specific Prevalence of Pouchitis
• Diagnosed Cases of Episodic and Chronic Pouchitis

Pouchitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pouchitis market or expected to get launched during the study period. The analysis covers Pouchitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pouchitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Discover more about therapies set to grab major Pouchitis market share @ Pouchitis market forecast 

Pouchitis Therapies and Key Companies

• Liraglutide: Novo Nordisk
• AMT-101: Applied Molecular Transport

Pouchitis Market Strengths

• The pathophysiology of the disease is well understood
• In the coming years, the incidence of this disease might increase

Scope of the Pouchitis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pouchitis Companies: Novo Nordisk, Applied Molecular Transport, Takeda Pharmaceutical Company Limited, AstraZeneca, Pfizer, Inc., GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, and others
• Key Pouchitis Therapies: Liraglutide, AMT-101, and others
• Pouchitis Therapeutic Assessment: Pouchitis current marketed and Pouchitis emerging therapies
• Pouchitis Market Dynamics: Pouchitis market drivers and Pouchitis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Pouchitis Unmet Needs, KOL’s views, Analyst’s views, Pouchitis Market Access and Reimbursement 

Pouchitis Market Unmet Needs

• Challenges in diagnoses
• Development of novel therapies
• Quality of life
• Poor disease understanding
• Antibiotic resistance

Table of Contents 

1. Pouchitis Market Report Introduction

2. Executive Summary for Pouchitis

3. SWOT analysis of Pouchitis

4. Pouchitis Patient Share (%) Overview at a Glance

5. Pouchitis Market Overview at a Glance

6. Pouchitis Disease Background and Overview

7. Pouchitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Pouchitis 

9. Pouchitis Current Treatment and Medical Practices

10. Pouchitis Unmet Needs

11. Pouchitis Emerging Therapies

12. Pouchitis Market Outlook

13. Country-Wise Pouchitis Market Analysis (2019–2032)

14. Pouchitis Market Access and Reimbursement of Therapies

15. Pouchitis Market Drivers

16. Pouchitis Market Barriers

17.  Pouchitis Appendix

18. Pouchitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Pouchitis treatment, visit @ Pouchitis Medications

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services